de en

Reagents and instruments for immunology, cell biology and molecular biology.

Monomethyl auristatin E [474645-27-7]

Print

Cat# HY-15162-10mg

Size : 10mg

Contact local distributor :

Phone : +1 850 650 7790

Brand : MedChemExpress

Request more information

Contact local distributor :

Phone : +1 850 650 7790

Datasheet

Description

Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.

IC₅₀ & Target

Auristatin

Cellular Effect

Cell Line	Type	Value	Description	References
A549	EC₅₀	0.0005 μM Compound: Monomethyl auristatin E	Antiproliferative activity against human A549 cells after 72 hrs by MTS assay Antiproliferative activity against human A549 cells after 72 hrs by MTS assay	[PMID: 28972755]
A549	IC₅₀	0.59 nM Compound: MMAE	Antiproliferative activity against human A549 cells after 4 days by XTT assay Antiproliferative activity against human A549 cells after 4 days by XTT assay	[PMID: 23845743]
A549	IC₅₀	1.3 nM Compound: 2; MMAE	Cytotoxicity against human A549 cells after 2 days by cell titer 96 aqueous one solution based assay Cytotoxicity against human A549 cells after 2 days by cell titer 96 aqueous one solution based assay	[PMID: 29454703]
BT-474	GI₅₀	0.22 nM Compound: 4, MMAE	Cytotoxicity against human BT474 cells assessed as cell viability incubated fore 4 days by MTS assay Cytotoxicity against human BT474 cells assessed as cell viability incubated fore 4 days by MTS assay	[PMID: 25431858]
BXPC-3	GI₅₀	> 1.39 nM Compound: 2b	Growth inhibition of human BxPC3 cells incubated for 48 hrs by MTT assay Growth inhibition of human BxPC3 cells incubated for 48 hrs by MTT assay	[PMID: 28211277]
BXPC-3	GI₅₀	> 1.39 nM Compound: Desmethylauristatin E	Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay	[PMID: 28926240]
BXPC-3	GI₅₀	> 1.39 nM Compound: Desmethylauristatin E	Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay	[PMID: 28895394]
CWR22R	CC₅₀	1.44 nM Compound: MMAE	Cytotoxicity against human 22Rv1 cells expressing PMSA measured using MTT assay Cytotoxicity against human 22Rv1 cells expressing PMSA measured using MTT assay	[PMID: 34797052]
DU-145	GI₅₀	0.418 nM Compound: 2b	Growth inhibition of human DU145 cells incubated for 48 hrs by MTT assay Growth inhibition of human DU145 cells incubated for 48 hrs by MTT assay	[PMID: 28211277]
DU-145	GI₅₀	0.418 nM Compound: Desmethylauristatin E	Growth inhibition of human DU145 cells after 48 hrs by SRB assay Growth inhibition of human DU145 cells after 48 hrs by SRB assay	[PMID: 28926240]
DU-145	GI₅₀	0.418 nM Compound: Desmethylauristatin E	Growth inhibition of human DU145 cells after 48 hrs by SRB assay Growth inhibition of human DU145 cells after 48 hrs by SRB assay	[PMID: 28895394]
DU-145	IC₅₀	0.55 nM Compound: MMAE	Cytotoxicity against human DU-145 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-96 assay Cytotoxicity against human DU-145 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-96 assay	[PMID: 36327103]
DU-145	IC₅₀	0.62 nM Compound: MMAE	Cytotoxicity against human DU-145 cells assessed as reduction in cell viability incubated for 72 hrs in presence of TTR by CellTiter-96 assay Cytotoxicity against human DU-145 cells assessed as reduction in cell viability incubated for 72 hrs in presence of TTR by CellTiter-96 assay	[PMID: 36327103]
HeLa	IC₅₀	1 nM Compound: MMAE	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs in presence of TTR by CellTiter-96 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs in presence of TTR by CellTiter-96 assay	[PMID: 36327103]
HeLa	IC₅₀	1.1 nM Compound: MMAE	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-96 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-96 assay	[PMID: 36327103]
HGC-27	IC₅₀	7.18 nM Compound: MMAE	Cytotoxicity against KK-LC-1-negative human HGC-27 cells incubated for 72 hrs by CCK-8 assay Cytotoxicity against KK-LC-1-negative human HGC-27 cells incubated for 72 hrs by CCK-8 assay	[PMID: 35932567]
KB	IC₅₀	0.19 nM Compound: MMAE	Antiproliferative activity against human KB cells after 4 days by XTT assay Antiproliferative activity against human KB cells after 4 days by XTT assay	[PMID: 23845743]
KM-20L2	GI₅₀	0.599 nM Compound: 2b	Growth inhibition of human KM20L2 cells incubated for 48 hrs by MTT assay Growth inhibition of human KM20L2 cells incubated for 48 hrs by MTT assay	[PMID: 28211277]
KM-20L2	GI₅₀	0.599 nM Compound: Desmethylauristatin E	Growth inhibition of human KM20L2 cells after 48 hrs by SRB assay Growth inhibition of human KM20L2 cells after 48 hrs by SRB assay	[PMID: 28926240]
KM-20L2	GI₅₀	0.599 nM Compound: Desmethylauristatin E	Growth inhibition of human KM20L2 cells after 48 hrs by SRB assay Growth inhibition of human KM20L2 cells after 48 hrs by SRB assay	[PMID: 28895394]
L1210	IC₅₀	2.1 nM Compound: 2; MMAE	Cytotoxicity against mouse L1210 cells after 2 days by cell titer 96 aqueous one solution based assay Cytotoxicity against mouse L1210 cells after 2 days by cell titer 96 aqueous one solution based assay	[PMID: 29454703]
LNCaP	IC₅₀	0.71 nM Compound: MMAE	Cytotoxicity against human LNCaP cells assessed as reduction in cell viability incubated for 72 hrs in presence of TTR by CellTiter-96 assay Cytotoxicity against human LNCaP cells assessed as reduction in cell viability incubated for 72 hrs in presence of TTR by CellTiter-96 assay	[PMID: 36327103]
LNCaP	IC₅₀	0.79 nM Compound: MMAE	Cytotoxicity against human LNCaP cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-96 assay Cytotoxicity against human LNCaP cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-96 assay	[PMID: 36327103]
MCF7	GI₅₀	0.404 nM Compound: 2b	Growth inhibition of human MCF7 cells incubated for 48 hrs by MTT assay Growth inhibition of human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 28211277]
MCF7	GI₅₀	0.404 nM Compound: Desmethylauristatin E	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay Growth inhibition of human MCF7 cells after 48 hrs by SRB assay	[PMID: 28926240]
MCF7	GI₅₀	0.404 nM Compound: Desmethylauristatin E	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay Growth inhibition of human MCF7 cells after 48 hrs by SRB assay	[PMID: 28895394]
MDA-MB-231	IC₅₀	0.25 nM Compound: MMAE	Antiproliferative activity against human MDA-MB-231 cells after 4 days by XTT assay Antiproliferative activity against human MDA-MB-231 cells after 4 days by XTT assay	[PMID: 23845743]
MDA-MB-361	GI₅₀	0.49 nM Compound: 4, MMAE	Cytotoxicity against human MDA-MB-361 cells assessed as cell viability incubated fore 4 days by MTS assay Cytotoxicity against human MDA-MB-361 cells assessed as cell viability incubated fore 4 days by MTS assay	[PMID: 25431858]
MKN-45	IC₅₀	10.7 nM Compound: MMAE	Cytotoxicity against KK-LC-1-positive human MKN-45 cells incubated for 72 hrs by CCK-8 assay Cytotoxicity against KK-LC-1-positive human MKN-45 cells incubated for 72 hrs by CCK-8 assay	[PMID: 35932567]
NCI-H460	GI₅₀	0.683 nM Compound: 2b	Growth inhibition of human NCI-H460 cells incubated for 48 hrs by MTT assay Growth inhibition of human NCI-H460 cells incubated for 48 hrs by MTT assay	[PMID: 28211277]
NCI-H460	GI₅₀	0.683 nM Compound: Desmethylauristatin E	Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 28926240]
NCI-H460	GI₅₀	0.683 nM Compound: Desmethylauristatin E	Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 28895394]
NCI-H524	IC₅₀	3.7 nM Compound: MMAE	Cytotoxicity in human NCI-H524 cells pre-incubated for 2 hrs followed by compound wash out and subsequently incubated for 70 hrs by Cell Titer Glo assay Cytotoxicity in human NCI-H524 cells pre-incubated for 2 hrs followed by compound wash out and subsequently incubated for 70 hrs by Cell Titer Glo assay	[PMID: 30735385]
NCI-N87	GI₅₀	0.54 nM Compound: 4, MMAE	Cytotoxicity against human NCI-N87 cells assessed as cell viability incubated fore 4 days by MTS assay Cytotoxicity against human NCI-N87 cells assessed as cell viability incubated fore 4 days by MTS assay	[PMID: 25431858]
NUGC-4	IC₅₀	10.97 nM Compound: MMAE	Cytotoxicity against KK-LC-1-positive human NUGC-4 cells incubated for 72 hrs by CCK-8 assay Cytotoxicity against KK-LC-1-positive human NUGC-4 cells incubated for 72 hrs by CCK-8 assay	[PMID: 35932567]
PC-3	CC₅₀	0.97 nM Compound: MMAE	Cytotoxicity against human PC-3 cells not expressing PMSA measured using MTT assay Cytotoxicity against human PC-3 cells not expressing PMSA measured using MTT assay	[PMID: 34797052]
SF-268	GI₅₀	0.432 nM Compound: 2b	Growth inhibition of human SF268 cells incubated for 48 hrs by MTT assay Growth inhibition of human SF268 cells incubated for 48 hrs by MTT assay	[PMID: 28211277]
SF-268	GI₅₀	0.432 nM Compound: Desmethylauristatin E	Growth inhibition of human SF268 cells after 48 hrs by SRB assay Growth inhibition of human SF268 cells after 48 hrs by SRB assay	[PMID: 28926240]
SF-268	GI₅₀	0.432 nM Compound: Desmethylauristatin E	Growth inhibition of human SF268 cells after 48 hrs by SRB assay Growth inhibition of human SF268 cells after 48 hrs by SRB assay	[PMID: 28895394]
SK-OV-3	IC₅₀	0.66 nM Compound: 2; MMAE	Cytotoxicity against human SKOV3 cells after 2 days by cell titer 96 aqueous one solution based assay Cytotoxicity against human SKOV3 cells after 2 days by cell titer 96 aqueous one solution based assay	[PMID: 29454703]
U-87MG ATCC	EC₅₀	0.0002 μM Compound: Monomethyl auristatin E	Antiproliferative activity against human U87 cells after 72 hrs by MTS assay Antiproliferative activity against human U87 cells after 72 hrs by MTS assay	[PMID: 28972755]

In Vitro

Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30⁺ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells^[1].
MMAE sensitizes colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolongs tumor regression in xenograft models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

717.98

Formula

C₃₉H₆₇N₅O₇

CAS No.

474645-27-7

Appearance

Solid

Color

White to yellow

SMILES

CC(C)[C@H](NC)C(N[C@H](C(N([C@@H]([C@@H](C)CC)[C@@H](CC(N1CCC[C@@]1(05)[C@H](OC)[C@@H](C)C(N[C@H](C)[C@H](C2=CC=CC=C2)O)=O)=O)OC)C)=O)C(C)C)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, sealed storage, away from moisture and light

*The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility

In Vitro:

Ethanol : 50 mg/mL (69.64 mM; Need ultrasonic)

DMSO : ≥ 48 mg/mL (66.85 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.3928 mL	6.9640 mL	13.9280 mL
5 mM	0.2786 mL	1.3928 mL	2.7856 mL
10 mM	0.1393 mL	0.6964 mL	1.3928 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: 2.62 mg/mL (3.65 mM); Clear solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.62 mg/mL (3.65 mM); Clear solution
Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 4

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 5

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 6

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 7

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 8

Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 9

Add each solvent one by one: 1% DMSO 99% Saline
Solubility: ≥ 0.52 mg/mL (0.72 mM); Clear solution

Purity & Documentation

Purity: 99.97%

Data Sheet (280 KB) SDS (645 KB)

COA (251 KB) HNMR (206 KB) RP-HPLC (263 KB)

Handling Instructions (2659 KB)

References

[1]. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897. [Content Brief]

[2]. Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87. [Content Brief]

You might also be interested by the following products:

Cat#

Description

Cond.

Price Bef. VAT

NB-64-06150-1mg

Calicheamicin [108212-75-5]

1mg

NB-64-09737-1mg

Mertansine [139504-50-0]

1mg

NB-64-06424-2mg

DM4 [796073-69-3]

2mg

Monomethyl auristatin E [474645-27-7]

Cat# HY-15162-10mg

Contact local distributor :

Brand : MedChemExpress

Contact local distributor :

Monomethyl auristatin E Related Antibodies

You might also be interested by the following products: